Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Top 10 Parkinson’s Disease Stories of 2022

Throughout 2022, Parkinson’s News Today brought you daily coverage of the latest scientific breakthroughs and treatment advancements related to Parkinson’s disease. Here are the 10 most-read articles of 2022, with a brief description of what made them interesting and relevant to the Parkinson’s community. We look forward to continuing…

Gene Therapy SLS-004 Prevents Neurodegeneration In Mouse Model

SLS-004, Seelos Therapeutics‘ investigational gene therapy for Parkinson’s disease, lowered alpha-synuclein levels and prevented the degeneration of dopamine-producing, or dopaminergic, neurons in a mouse model of the disease, the company announced. A hallmark of the neurodegenerative disease, the loss of dopaminergic neurons in a brain region called the…

AL101 Safely Increases Progranulin Levels in Phase 1 Trial

Multiple doses of AL101, Alector’s investigational treatment for neurodegenerative diseases such as Parkinson’s, safely increased progranulin levels in healthy volunteers, according to data from a Phase 1 clinical trial. Low levels of progranulin, a protein critical for immune activity and cell survival in the nervous system, have been…

Cholesterol Med Fails to Slow Disease Progression

Treatment with simvastatin, a medication used to lower cholesterol levels, did not slow the progression of Parkinson’s disease  over a two-year period, according to published data from a Phase 2 trial. Overall, the data provide “no evidence to support proceeding to a phase 3 trial,” the researchers wrote, noting…

Generic Rotigotine Transdermal Patch Ready for Trial, XPhyto Says

XPhyto Therapeutics’ generic version of the Neupro patch for Parkinson’s disease is showing that its active ingredient, rotigotine, can be absorbed through the skin in ways similar to the brand-name product, the company announced. Findings, in work using skin from human cadavers and an optimized formula for the generic patch, support…

Certain Nonmotor Symptoms Predict Anxiety In Parkinson’s

REM sleep behavior disorder (RBD) and autonomic dysfunction (dysautonomia), two types of nonmotor Parkinson’s disease symptoms, were significant predictors of anxiety in Parkinson’s patients over a three-year study. More than half (57%) of patients in in the study met the clinical criteria for anxiety at some point, underscoring its…